In this work, CHT has also proven to be a potential candidate to be used as a carrier for therapeutic agents in a lung cancer situation, since it has a higher release percentage (80% release after 10 h) at an acidic pH condition (lung cancer pH). The gene discussed is SLC5A7; the disease is lung carcinoma.